Literature DB >> 16939817

Development of human-human hybridoma from anti-Her-2 peptide-producing B cells in immunized NOG mouse.

Yoshie Kametani1, Masashi Shiina, Ikumi Katano, Ryoji Ito, Kiyoshi Ando, Kanae Toyama, Hideo Tsukamoto, Takuya Matsumura, Yuki Saito, Dai Ishikawa, Takao Taki, Mamoru Ito, Kohzoh Imai, Yutaka Tokuda, Shunichi Kato, Norikazu Tamaoki, Sonoko Habu.   

Abstract

OBJECTIVE: Numerous monoclonal antibodies have been developed for the purpose of medical treatments, including cancer treatment. For clinical application, the most useful are human-derived antibodies. In this study, we tried to prepare designed antigen-specific antibodies of completely human origin using immunodeficient mouse.
METHODS: Nonobese diabetic/severe combined immunodeficient/IL-2 receptor gamma null mouse (NOG) mouse was used to reconstitute the human immune system with umbilical cord blood hematopoietic stem cells (CB-NOG mouse) and to prepare human-derived Her-2-epitope-specific antibodies. Hybridoma lines were prepared by fusing the human myeloma cell line Karpas707H.
RESULTS: Serum of immunized NOG mouse contained human-derived immunoglobulin M (IgM) antibodies specific for a short peptide sequence of 20 amino acids, including the epitope peptide of apoptotic Her-2 antibody CH401. Hybridoma lines were successfully prepared with spleen B cells obtained from the immunized CB-NOG mouse. One of these cell lines produced human IgM against the epitope peptide that can recognize surface Her-2 molecule.
CONCLUSION: We could produce human-derived IgM antibody against Her-2 epitope peptide in CB-NOG mouse, succeeding in generation of human hybridoma-secreting IgM against a given peptide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16939817     DOI: 10.1016/j.exphem.2006.05.006

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  6 in total

1.  A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production.

Authors:  Hua Yu; Chiara Borsotti; Jean-Nicolas Schickel; Shu Zhu; Till Strowig; Elizabeth E Eynon; Davor Frleta; Cagan Gurer; Andrew J Murphy; George D Yancopoulos; Eric Meffre; Markus G Manz; Richard A Flavell
Journal:  Blood       Date:  2017-01-11       Impact factor: 22.113

Review 2.  Overcoming current limitations in humanized mouse research.

Authors:  Michael A Brehm; Leonard D Shultz; Jeremy Luban; Dale L Greiner
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

3.  Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.

Authors:  C De Giovanni; G Nicoletti; L Landuzzi; F Romani; S Croci; A Palladini; A Murgo; A Antognoli; M L Ianzano; V Stivani; V Grosso; M Iezzi; L Stramucci; E Barbieri; R M Lemoli; P Nanni; P-L Lollini
Journal:  Br J Cancer       Date:  2012-08-28       Impact factor: 7.640

Review 4.  Increasing hematopoietic stem cell yield to develop mice with human immune systems.

Authors:  Juan-Carlos Biancotti; Terrence Town
Journal:  Biomed Res Int       Date:  2013-02-14       Impact factor: 3.411

Review 5.  Comparative immunity of antigen recognition, differentiation, and other functional molecules: similarities and differences among common marmosets, humans, and mice.

Authors:  Yoshie Kametani; Takashi Shiina; Ryuji Suzuki; Erika Sasaki; Sonoko Habu
Journal:  Exp Anim       Date:  2018-03-08

Review 6.  Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors.

Authors:  Yoshie Kametani; Yusuke Ohno; Shino Ohshima; Banri Tsuda; Atsushi Yasuda; Toshiro Seki; Ryoji Ito; Yutaka Tokuda
Journal:  Int J Mol Sci       Date:  2019-12-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.